Aduro BioTech Inc (NASDAQ:ADRO) received a $30.00 target price from Canaccord Genuity in a report issued on Monday. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity’s price objective would indicate a potential upside of 184.36% from the stock’s current price.
A number of other equities analysts also recently commented on the stock. FBR & Co reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Aduro BioTech in a report on Tuesday, March 7th. Roth Capital reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Aduro BioTech in a report on Tuesday, March 7th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $21.00.
Shares of Aduro BioTech (NASDAQ:ADRO) traded up 1.185% during trading on Monday, hitting $10.675. 261,177 shares of the stock were exchanged. The stock’s market cap is $725.88 million. The stock has a 50-day moving average of $11.15 and a 200 day moving average of $11.98. Aduro BioTech has a 12-month low of $7.26 and a 12-month high of $16.43.
In other news, EVP Dirk G. Brockstedt sold 8,000 shares of the business’s stock in a transaction on Tuesday, January 17th. The shares were sold at an average price of $11.86, for a total transaction of $94,880.00. Following the completion of the transaction, the executive vice president now owns 57,300 shares of the company’s stock, valued at $679,578. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Blaine Templeman sold 3,785 shares of the business’s stock in a transaction on Wednesday, January 11th. The shares were sold at an average price of $11.95, for a total transaction of $45,230.75. The disclosure for this sale can be found here. In the last ninety days, insiders sold 99,331 shares of company stock valued at $1,114,935. 6.50% of the stock is currently owned by corporate insiders.
Several institutional investors have recently made changes to their positions in ADRO. Tudor Investment Corp Et Al purchased a new position in shares of Aduro BioTech during the fourth quarter valued at about $131,000. Wells Fargo & Company MN increased its position in shares of Aduro BioTech by 1.1% in the third quarter. Wells Fargo & Company MN now owns 12,258 shares of the company’s stock valued at $152,000 after buying an additional 139 shares during the period. Fox Run Management L.L.C. purchased a new position in shares of Aduro BioTech during the third quarter valued at about $174,000. Zacks Investment Management increased its position in shares of Aduro BioTech by 43.9% in the third quarter. Zacks Investment Management now owns 16,801 shares of the company’s stock valued at $209,000 after buying an additional 5,122 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in shares of Aduro BioTech during the fourth quarter valued at about $241,000. 35.52% of the stock is owned by institutional investors.
Aduro BioTech Company Profile
Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.